From 1978 to 1983, one hundred and nine patients with cancer of the hypopharynx (93 cases) and the cervical esophagus (16 cases) were treated at our hospital. They were evaluated for the sex, the age, the symptom, the primary site, TNM classification, the stage, habits of smoking and drinking, past history of irradiation, sputum cytology, the treatment modality and multiple primary cancer.
Eighty seven percent of the patients with cancer of the hypopharynx visited us so late with advanced stage III or stage IV. For earlier diagnosis, screening of the high risk group complaining of the throat discomfort should be done routinely. Especially in sputum cytology, positive rate was high in 79.5 percent (35/44) of the patients in all stages, and 66.7 percent even in T
1 cases, indicating that this cytology was significantly useful for the detection of cancer of the hypopharynx and cervical esophagus.
After January, 1984, 13 advanced new patients (8 of stage III and 5 of stage IV) were treated with neo-adjuvant combination chemotherapy which included cisplatin, peplomycin; cisplatin peplomycin, methotrexate; cisplatin, bleomycin, methotrexate over two courses of the therapy. The response rate (CR+PR) was high, 90 percent to the primary tumor and 77.8 percent to the metastatic node. All except for one case received operation and/or radiotherapy after chemotherapy. It seems that a neo-adjuvant chemotherapy prior to operation and/or radio therapy including cisplatin and other agents is very useful as a multidisciplinary treatment in cancer of the hypopharynx and the cervical esophagus.
View full abstract